Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Tivozanib vs Sorafenib in Advanced Renal Cell Carcinoma
2009-013219-37Phase 3Completed
- Sponsor
- AVEO Oncology
- Start
- Oct 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tivozanib in renal cell carcinoma (RCC) (2 arms), sponsored by AVEO Oncology. Primary endpoints: Progression-free survival and Overall survival. Started Oct 2009; status: completed.
02
Drugs
tivozanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2009-013219-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013219-37.